Predictors of early response to infliximab in patients with ulcerative colitis.

摘要: Background: Our objective is to report the outcome of infliximab (IFX) in ulcerative colitis (UC) patients from a single center and identify predictors early clinical response. Methods: The first 100 UC (45 female; median age, 37.9 years) who received IFX at were included. Eighty-four 5 mg/kg IFX, 37 3-dose induction weeks 0, 2, 6. Mayo endoscopic subscore, assessed by sigmoidoscopy before inclusion, was 1, 3 5%, 52%, 43% patients, respectively. Sixty percent had pancolitis, 63% on concomitant immunosuppressive therapy, 9% active smokers, 64% C-reactive protein ≥5 mg/dL, 44% pANCA+/ASCA−. Five because severe acute refractory intravenous corticosteroids. Results: Early complete partial responses observed 41% 24% patients. Patients with response significantly younger than nonresponders (median 35.7 versus 41.6 years, P = 0.041). pANCA+/ASCA− lower (55% 76%; odds ratio [OR] 0.40 (0.16–0.99), 0.049). Concomitant therapy use an scheme did not influence response. Only 1 for steroid-refractory required colectomy within 2 months. Conclusions: efficient UC, as shown 65% A serotype older age infusion are associated suboptimal response. (Inflamm Bowel Dis 2006)